Erenumab in the treatment of migraine-Reference-Cited by-同舟云学术

Erenumab in the treatment of migraine

Published:2018-11-01 Issue:6 Volume:8 Page:415-426
ISSN:1758-1869
Container-title:Pain Management
language:en
Short-container-title:Pain Management

Author:

Jain Sameer¹,Yuan Hsiangkuo²,Spare Nicole³,Silberstein Stephen D³

Affiliation:

1. Department of Pain Medicine, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA

2. Department of Neurology, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA

3. Jefferson Headache Center, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA

Abstract

Migraine is a highly prevalent neurological pain syndrome, and its management is limited due to side effects posed by current preventive therapies. Calcitonin gene-related peptide (CGRP) plays a crucial role in the pathogenesis of migraine. In recent years, research has been dedicated to the development of monoclonal antibodies against CGRP and CGRP receptors for the treatment of migraine. This review will focus on the first US FDA-approved CGRP-receptor monoclonal antibody developed for the prevention of migraine: erenumab. Two Phase II trials (one for episodic migraine and one for chronic migraine) and two Phase III trials for episodic migraine have been published demonstrating the efficacy and safety of erenumab in the prevention of migraine.

Publisher

Future Medicine Ltd

Subject

General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/pmt-2018-0037

Reference95 articles.

1. World Health Organization: headache disorders (2016). www.who.int/mediacentre/factsheets/fs277/en/.

2. Center Disease of Control. Summary health statistics: National Health Interview Survey, 2016 (2016). https://ftp.cdc.gov/pub/Health_Statistics/NCHS/NHIS/SHS/2016_SHS_Table_A-5.pdf.

3. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition

4. Depression and risk of transformation of episodic to chronic migraine

5. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness of Anti-Calcitonin Gene-Related Peptide Medication in Vestibular Migraine: A Retrospective Cohort Study in an Asian Population;CNS Drugs;2024-05-29

2. Cardiovascular Adverse Drug Reactions of Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies for Migraine Prevention: An Analysis from the European Spontaneous Adverse Event Reporting System;BioDrugs;2024-02-25

3. Efficacy of Probiotics in Prevention of Migraine Attacks in Children: A Randomized Clinical Trial Study;IRAN J CHILD NEUROL;2024

4. Efficacy of Melatonin Administration in Reducing Headaches in Children with Migraines without Sleep Disorders;IRAN J CHILD NEUROL;2024

5. Characteristics associated with response to subcutaneously administered anti‐CGRP monoclonal antibody medications in a real‐world community cohort of persons living with migraine: A retrospective clinical and genetic study;Headache: The Journal of Head and Face Pain;2023-12-10